Race Oncology Limited
Status: Publicly traded
Direct answer
Race Oncology Limited is publicly traded on ASX under the ticker RAC.AX.
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma,...
Can you invest in Race Oncology Limited?
Yes. Race Oncology Limited trades publicly on ASX as RAC.AX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Race Oncology Limited
Detailed equity research is provided by MarketSnap.